Current Renal Cancer chemotherapy regimens are listed here.
https://www.cancertherapyadvisor.co...mens/renal-cell-carcinoma-treatment-regimens/
The combination of OPDIVIO and YERVOY seems to be the leading treatment. It looks like Sutent was the previous standard of care.
https://www.opdivo.com/advanced-ren...on/about-opdivo-yervoy/clinical-trial-results
So what's the opportunity for Bisantrene:
- OPDIVIO is a PD-1 inhibitor
- PD-1 inhibitors are susceptible to resistance
https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-020-00212-5- Inhibiting FTO can make PD-1 inhibitors work better (that's been shown for Melanoma)
https://www.nature.com/articles/s41467-019-10669-0- 90% of ccRCC are caused by mutations in the von Hippel-Lindau (VHL) tumour suppressor gene
https://www.researchgate.net/public...in_Sporadic_Conventional_Renal_Cell_Carcinoma- FTO was found to be synthetically lethal in cells with inactive VHL. Inhibition of FTO was found to kill VHL(-) ccRCC cancers.
https://pubmed.ncbi.nlm.nih.gov/32817424/
I can see a head to head battle between BMS and Merck and potentially a keen interest in what Bisantrene could do to make their PD-1 inhibitors work better.
-
- There are more pages in this discussion • 2,935 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.055(4.55%) |
Mkt cap ! $206.7M | |||
| Open | High | Low | Value | Volume |
| $1.22 | $1.22 | $1.16 | $134.5K | 114.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1762 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 966 | 2 |
View Market Depth
| Last trade - 12.50pm 03/07/2025 (20 minute delay) ? |
| RAC (ASX) Chart |